先进疗法治疗中重度溃疡性结肠炎早期症状缓解速度比较:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入截至2022年12月31日的随机试验,比较获批疗法治疗成人中重度溃疡性结肠炎在第2、4、6周的症状缓解率。乌帕替尼在第2、4、6周均比所有药物更有效,奥扎尼莫德起效相对较慢。
要点
- 乌帕替尼在第2、4、6周的症状缓解效果均优于所有其他获批药物。
- 第2周时TNFα拮抗剂和filgotinib优于奥扎尼莫德,但第4、6周无此差异。
- 乌司奴单抗和维得利珠单抗仅在生物制剂初治患者中实现快速缓解。
核心结论
- 在中重度溃疡性结肠炎成人门诊患者中,乌帕替尼实现早期症状缓解最有效,奥扎尼莫德起效相对较慢。
研究设计与样本
- 系统综述与随机效应网络Meta分析,采用频率学方法,检索截至2022年12月31日的随机试验。
- 纳入成人中重度溃疡性结肠炎门诊患者,比较获批疗法(TNFα拮抗剂、维得利珠单抗、乌司奴单抗、JAK抑制剂或奥扎尼莫德)之间或与安慰剂的症状缓解率。
主要发现
- 乌帕替尼在第2周(RR范围2.85-6.27)、第4周(RR范围1.78-2.37)、第6周(RR范围1.84-2.79)的症状缓解均优于所有其他药物。
- 第2周时TNFα拮抗剂和filgotinib优于奥扎尼莫德,但第4、6周无此差异;乌司奴单抗和维得利珠单抗在第2周未优于奥扎尼莫德。
- 以安慰剂组约10%患者第2周达症状缓解为基准,估计乌帕替尼、filgotinib、英夫利西单抗、阿达木单抗、戈利木单抗、乌司奴单抗、维得利珠单抗和奥扎尼莫德组分别有68%、22%、23.7%、23.9%、22.2%、18.4%、15.7%和10.9%的患者可实现早期症状缓解。
- 乌司奴单抗和维得利珠单抗仅在生物制剂初治患者中实现快速缓解。
关键数值与推荐
- 症状缓解基于部分Mayo评分,要求直肠出血消失且排便频率接近正常,评估时间点为第2、4和/或6周。
- 效应量为相对风险(RR)及95%置信区间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rapidity of symptom resolution informs treatment choice in patients with moderate-severe ulcerative colitis (UC). We conducted a systematic review and network meta-analysis comparing early symptomatic remission with approved therapies. METHODS: Through a systematic literature review to December 31, 2022, we identified randomized trials in adult outpatients with moderate-severe UC treated with approved therapies (tumor necrosis factor α antagonists, vedolizumab, ustekinumab, janus kinase inhibitors, or ozanimod), compared with each other or placebo, reporting rates of symptomatic remission (based on partial Mayo score, with resolution of rectal bleeding and near-normalization of stool frequency) at weeks 2, 4, and/or 6. We performed random-effects network meta-analysis using a frequentist approach and estimated relative risk (RR) and 95% confidence interval values. RESULTS: On network meta-analysis, upadacitinib was more effective than all agents in achieving symptomatic remission at weeks 2 (range of RR, 2.85-6.27), 4 (range of RR, 1.78-2.37), and 6 (range of RR, 1.84-2.79). Tumor necrosis factor α antagonists and filgotinib, but not ustekinumab and vedolizumab, were more effective than ozanimod in achieving symptomatic remission at week 2, but not at weeks 4 and 6. With approximately 10% placebo-treated patients achieving symptomatic remission at 2 weeks, we estimated 68%, 22%, 23.7%, 23.9%, 22.2%, 18.4%, 15.7%, and 10.9% of upadacitinib-, filgotinib-, infliximab-, adalimumab-, golimumab-, ustekinumab-, vedolizumab-, and ozanimod-treated patients would achieve early symptomatic remission, ustekinumab and vedolizumab achieving rapid remission only in biologic-naïve patients. DISCUSSION: In a systematic review and network meta-analysis, upadacitinib was most effective in achieving early symptomatic remission, whereas ozanimod was relatively slower acting.
引用
- Ahuja D, Murad MH, Ma C, et al. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2023. PMID: 36976548. doi:10.14309/ajg.0000000000002263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。